Company Carisma Therapeutics, Inc.

Equities

CARM

US14216R1014

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Carisma Therapeutics, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 03:47:08 2024-04-23 pm EDT			5-day change	1st Jan Change
1.68 ^USD	-10.16%		+1.18%	-41.30%

Apr. 11	BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target	MT
Apr. 02	HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating	MT

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the treatment of solid tumors. Its first product candidate, CT-0508, is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2). Its second product candidate, CT-0525, is an ex vivo gene-modified autologous chimeric antigen receptor-macrophage (CAR-Macrophage) cellular therapy intended to treat solid tumors that overexpress HER2. CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors.

Number of employees: 107

Managers	Title	Age	Since
Michael Klichinsky FOU	Founder	34	15-12-31
Steven Kelly CEO	Chief Executive Officer	59	18-01-31
Richard Morris DFI	Director of Finance/CFO	51	21-05-31
Daniel Cushing CTO	Chief Tech/Sci/R&D Officer	-	16-12-31
Tom Wilton PRN	Corporate Officer/Principal	-	19-08-31
Terry Shields HRO	Human Resources Officer	-	23-06-13
Eric Siegel LAW	General Counsel	60	23-06-13

Members of the board	Title	Age	Since
Steven Kelly CEO	Chief Executive Officer	59	18-01-31
Sanford Zweifach CHM	Chairman	68	21-10-31
Björn Ingemar Odlander BRD	Director/Board Member	66	22-01-31
Regina Hodits BRD	Director/Board Member	54	18-05-31
Briggs Morrison BRD	Director/Board Member	65	20-06-30
Michael Torok BRD	Director/Board Member	45	23-03-06

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	41,542,534	27,945,479 ( 67.27 %)	0	67.27 %

Name	Equities	%	Valuation
MODERNA, INC. 12.54 %	5,059,338	12.54 %	11 M $
HealthCap AB 8.421 %	3,398,248	8.421 %	8 M $
ABBVIE INC. 6.814 %	2,749,855	6.814 %	6 M $
IP Group Plc /Venture Capital/ 6.723 %	2,713,232	6.723 %	6 M $
Regina Hodits 5.693 %	2,297,546	5.693 %	5 M $
Chidozie Ugwumba 5.491 %	2,215,877	5.491 %	5 M $
BlackRock Advisors LLC 4.433 %	1,789,037	4.433 %	4 M $
TPG Group Holdings (SBS) Advisors, Inc. 4.173 %	1,684,062	4.173 %	4 M $
Vanguard Fiduciary Trust Co. 3.887 %	1,568,761	3.887 %	4 M $
University of Pennsylvania (Investment) 3.103 %	1,252,107	3.103 %	3 M $

Carisma Therapeutics, Inc.

3675 Market Street Suite 401

19104, Philadelphia

http://carismatx.com

address Carisma Therapeutics, Inc.(CARM)

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.87 USD

Average target price

8.4 USD

Spread / Average Target

+349.20%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CARISMA THERAPEUTICS, INC.	-41.30%	77.68M
VERTEX PHARMACEUTICALS INCORPORATED	-0.24%	103B
REGENERON PHARMACEUTICALS, INC.	+3.37%	96.73B
ARGENX SE	+1.66%	21.31B
BIONTECH SE	-16.39%	21.21B
GENMAB A/S	-6.82%	18.79B
WUXI APPTEC CO., LTD.	-41.41%	16.37B
BEIGENE, LTD.	-23.09%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+6.89%	13.44B
SAREPTA THERAPEUTICS, INC.	+22.06%	10.98B

Bio Therapeutic Drugs